B. Riley Has Negative Outlook of CAPR FY2026 Earnings

Key Points

• B. Riley has cut its FY2026 earnings per share estimate for Capricor Therapeutics from $1.37 to $1.27, while maintaining a "Strong-Buy" rating on the stock.
• Capricor's stock recently traded down by 3.2%, reaching $8.04, with a significant gap between its 52-week low of $3.84 and high of $23.40.
• Various brokerages have adjusted their price targets for Capricor, with estimates ranging from $12.00 to $40.00, reflecting mixed sentiments among analysts.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities research analysts at B. Riley lowered their FY2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report released on Tuesday, August 12th. B. Riley analyst M. El-Saadi now expects that the biotechnology company will post earnings of $1.27 per share for the year, down from their prior forecast of $1.37. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics' FY2028 earnings at $1.36 EPS and FY2029 earnings at $2.49 EPS.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

Several other brokerages also recently commented on CAPR. Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. HC Wainwright dropped their price target on Capricor Therapeutics from $77.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday, July 11th. Piper Sandler reissued an "overweight" rating and set a $20.00 price target on shares of Capricor Therapeutics in a research report on Friday, July 11th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Jones Trading dropped their price target on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, June 25th. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $22.56.

Capricor Therapeutics Trading Up 2.3%

CAPR traded up $0.18 on Thursday, hitting $7.96. 1,253,578 shares of the company's stock traded hands, compared to its average volume of 1,881,245. The company's 50 day simple moving average is $9.17 and its 200-day simple moving average is $10.93. The firm has a market cap of $363.93 million, a price-to-earnings ratio of -4.85 and a beta of 0.59. Capricor Therapeutics has a one year low of $3.84 and a one year high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. raised its position in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after buying an additional 2,947 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock valued at $67,000 after buying an additional 4,976 shares during the period. Virtus ETF Advisers LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter valued at $68,000. Finally, Citizens Financial Group Inc. RI purchased a new stake in shares of Capricor Therapeutics in the 1st quarter valued at $95,000. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.